milliplex sars-cov-2 antigen panel kits Search Results


milliplex sars-cov-2 antigen panel kits  (Merck & Co)
90
Merck & Co milliplex sars-cov-2 antigen panel kits
Kinetics of plasmablast proportions and <t>SARS-CoV-2</t> specific immunoglobulin enrichment delineated disease stages during mild-to-moderate COVID-19. ( A ) Representative pseudocolor plots of CD38 and CD27 expression data of CD19 + CD45RA + B lymphocytes showed the disease stage-dependent increase of plasmablast proportions (rectangular gate). ( B ) Top left: Quantitative data of plasmablast abundances at different disease stage. Top right, bottom left and bottom right: Semi-quantitative data of SARS-CoV-2 specific IgM, IgG and IgA titers in plasma samples. The data for anti-RBD, -S1, -S2 and –N were combined for IgM and IgG, respectively.* p < 0.05; ** p < 0.01; *** p < 0.001; Tukey-Kramer test for plasmablasts, Kruskal-Wallis test with Dunn’s correction for multiple comparisons for Antibody isotypes. MFI: Median fluorescence intensity. A 450 : Absorbance at 450 nm.
Milliplex Sars Cov 2 Antigen Panel Kits, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/milliplex sars-cov-2 antigen panel kits/product/Merck & Co
Average 90 stars, based on 1 article reviews
milliplex sars-cov-2 antigen panel kits - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Kinetics of plasmablast proportions and SARS-CoV-2 specific immunoglobulin enrichment delineated disease stages during mild-to-moderate COVID-19. ( A ) Representative pseudocolor plots of CD38 and CD27 expression data of CD19 + CD45RA + B lymphocytes showed the disease stage-dependent increase of plasmablast proportions (rectangular gate). ( B ) Top left: Quantitative data of plasmablast abundances at different disease stage. Top right, bottom left and bottom right: Semi-quantitative data of SARS-CoV-2 specific IgM, IgG and IgA titers in plasma samples. The data for anti-RBD, -S1, -S2 and –N were combined for IgM and IgG, respectively.* p < 0.05; ** p < 0.01; *** p < 0.001; Tukey-Kramer test for plasmablasts, Kruskal-Wallis test with Dunn’s correction for multiple comparisons for Antibody isotypes. MFI: Median fluorescence intensity. A 450 : Absorbance at 450 nm.

Journal: Viruses

Article Title: Distinguishing Incubation and Acute Disease Stages of Mild-to-Moderate COVID-19

doi: 10.3390/v14020203

Figure Lengend Snippet: Kinetics of plasmablast proportions and SARS-CoV-2 specific immunoglobulin enrichment delineated disease stages during mild-to-moderate COVID-19. ( A ) Representative pseudocolor plots of CD38 and CD27 expression data of CD19 + CD45RA + B lymphocytes showed the disease stage-dependent increase of plasmablast proportions (rectangular gate). ( B ) Top left: Quantitative data of plasmablast abundances at different disease stage. Top right, bottom left and bottom right: Semi-quantitative data of SARS-CoV-2 specific IgM, IgG and IgA titers in plasma samples. The data for anti-RBD, -S1, -S2 and –N were combined for IgM and IgG, respectively.* p < 0.05; ** p < 0.01; *** p < 0.001; Tukey-Kramer test for plasmablasts, Kruskal-Wallis test with Dunn’s correction for multiple comparisons for Antibody isotypes. MFI: Median fluorescence intensity. A 450 : Absorbance at 450 nm.

Article Snippet: For the semi-quantitative analyses of IgM and IgG specific for the nucleocapsid (N) or the spike protein subunits S1, S2 and receptor binding domain (RBD), we used the respective MILLIPLEX SARS-CoV-2 antigen panel kits (Merck) to the manufacturer’s instructions.

Techniques: Expressing, Fluorescence